Video Experimental Relacionado

Updated: Jul 17, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Impacto beneficioso del precondicionamiento durante la PTCA en la liberación de creatina quinasa

¹Division of Cardiology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. wlaskey@medicine.ab.umd.edu

|April 27, 1999

Resumen

El precondicionamiento isquémico durante la angioplastia coronaria transluminal percutánea (PTCA) reduce significativamente la necrosis miocárdica, indicada por niveles más bajos de creatina quinasa (CK). Este hallazgo apoya la relevancia clínica del precondicionamiento en pacientes de alto riesgo sometidos a PTCA.

Área de la Ciencia:

Cardiología Cardiología.
Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular
Enfermedad Isquémica del Corazón.

Sus antecedentes:

Estudios previos sugieren que el precondicionamiento isquémico reduce la disfunción durante la PTCA.
La relevancia clínica de estos hallazgos en humanos sigue sin estar clara.
Este estudio investiga si el precondicionamiento mediado por PTCA reduce la necrosis miocárdica.

Objetivo del estudio:

Para comprobar si la angioplastia coronaria transluminal percutánea (PTCA) realizada para provocar el precondicionamiento isquémico reduce la necrosis miocárdica.
Para evaluar la necrosis miocárdica mediante la medición de los niveles de creatina quinasa (CK) después del procedimiento.

Principales métodos:

150 pacientes con síndromes isquémicos inestables sometidos a PTCA fueron asignados al azar.
Los pacientes recibieron un protocolo de precondicionamiento (PC) mediado por PTCA validado o un enfoque sin restricciones (UC).
Los niveles de creatina quinasa (CK) se midieron después del procedimiento a las 8, 12 y 24 horas.

Principales resultados:

Las tasas de éxito clínico fueron similares entre los grupos de precondicionamiento (PC) y de control sin restricciones (UC).
La frecuencia de elevación de la creatina quinasa (CK) fue significativamente menor en el grupo PC (7,1%) en comparación con el grupo UC (25%).
El análisis multivariable confirmó que el precondicionamiento redujo significativamente la liberación de CK.

Conclusiones:

Un protocolo estandarizado para provocar el precondicionamiento isquémico durante la PTCA reduce significativamente la elevación de la creatina quinasa (CK).
Estos resultados demuestran la relevancia clínica del precondicionamiento isquémico en sujetos humanos.
El precondicionamiento es eficaz para reducir la necrosis miocárdica en poblaciones de pacientes de alto riesgo sometidos a PTCA.

Más Videos Relacionados

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Videos de Conceptos Relacionados

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...